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Abstract 40 
Objective: Migraine is a highly disabling disease affecting a significant proportion of the 41 
Australian population. The Methylenetetrahydrofolate Reductase (MTHFR) C677T variant 42 
has been associated with increased levels of homocysteine and risk of migraine with aura 43 
(MA). Folic acid, Vitamin B6 and B12 supplementation has been previously shown to reduce 44 
increased levels of homocysteine and decrease migraine symptoms. However the influence of 45 
dietary folate intake on migraine has been unclear. The aim of the current study was to 46 
analyse the association of dietary folate intake in the form of dietary folate equivalent (DFE), 47 
folic acid (FA) and total food folate (TFF) on migraine frequency, severity and disability.. 48 
Methods: A cohort of 141 adult females of Caucasian descent with MA was genotyped for 49 
the MTHFRC677T variant using restriction enzyme digestion. Dietary folate information was 50 
collected from all participants and analysed using the “FoodWorks” 2009 package. Folate 51 
consumption was compared to migraine frequency, severity and disability using linear 52 
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regression. Results: A significant inverse relation was observed between DFE [R2= 0.201, P= 53 
0.045, CI (-0.004, -0.001)] and FA [R2= 0.255, P= 0.036, 95% CI (-0.009, -0.002)] 54 
consumption and migraine frequency. It was also observed that in individuals with the CC 55 
genotype for the MTHFR C677T variant, migraine frequency was significantly linked to FA 56 
consumption [R2= 0.077, P= 0.029, CI (-0.009, -0.005)].Conclusions: The results from this 57 
study indicate that folate intake in the form of folic acid may influence migraine frequency in 58 
female MA sufferers. 59 
 60 
  Background 61 
 Migraine is an extremely debilitating and highly prevalent neurovascular disorder presenting 62 
multiple symptoms [1]. Migraine affects a significant proportion of the Australian population, 63 
thus placing a large economic burden on the economy [2]. The International Headache 64 
Society (IHS) has subdivided migraine into two broad categories of migraine with aura (MA) 65 
and migraine without aura (MO) [3]. MA has been linked to the Methylenetetrahydrofolate 66 
reductase gene mutation C677T [4, 5]. Individuals with the MTHFR C677T variant have 67 
shown diminished capacity to remethylate homocysteine to methionine, consequently 68 
inducing the increase in circulating plasma homocysteine levels [4-7]. Elevated homocysteine 69 
levels have been shown to be an independent risk factor for cardiovascular disease as well as 70 
being associated with endothelial dysfunction [8, 9]. While alteration in vascular function and 71 
cerebral blood flow has been identified in MA sufferers, the exact role vascular dysfunction 72 
plays in migraine pathogenesis is yet to be unravelled [10, 11].  73 
The B group vitamins are crucial co-enzymes in the maintenance of homocysteine 74 
homeostasis via the Methylation Cycle and deficiencies in these vitamins have been 75 
implicated in hyperhomocysteinemia[12]. Folic acid, B6 and B12 supplementation have been 76 
previously shown to reduce migraine disability, frequency and severity in MA sufferers [6, 77 
13, 14]. However the effects of dietary B vitamin consumption on migraine severity, 78 
frequency and disability are yet to be determined. The aim of the current study was to analyse 79 
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the consumption of dietary folate among a cohort of adult females with MA and to determine 80 
if there is an association between the levels of folate consumption, MTHFR genotype, 81 
migraine frequency, severity and disability prevalence. 82 
  83 
Methods 84 
Study Design and participant group 85 
This study involved the secondary analysis of data collected from a randomised, double 86 
blind, placebo controlled clinical trial on the effects of vitamin B supplementation and 87 
MTHFR and Methionine Synthase Reductase (MTRR) genotype on migraine disability, 88 
severity and frequency [14]. The clinical trial investigating the effects of vitamin B 89 
supplementation and MTHFR and MTRR genotype of migraine disability, severity and 90 
frequency was registered with Australian New Zealand Clinical Trial Registry (ANZCTR)         91 
and had previously obtained ethical approval from the Griffith University Ethics Committee 92 
for experimentation on human subjects. The analysis of the current study was included in the 93 
approval. The intervention period for this trial was 6 months with serum folate and plasma 94 
homocysteine levels recorded at baseline and at the end of the trial. MTHFR genotype was 95 
determined and migraine disability and frequency was also recorded. Participants of the 96 
clinical trial were asked to complete diet diaries which were used to analyse the composition 97 
of dietary folate intake [Total Food Folate (TFF), Folic Acid (FA) and Dietary Folate 98 
Equivalents (DFE)]. Pretrial data (Baseline measurement) from the participants was used for 99 
the dietary analysis. The baseline folate intake of the participants was compared to the 100 
baseline measurements of plasma homocysteine, serum folate, MTHFR C677T variant, 101 
migraine severity, frequency and disability.  102 
  103 
Patient group 104 
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In total 245 Caucasian females with MA of European ancestry between the ages of 18 and 65 105 
were recruited from Australia and were randomly assigned either the placebo group or 106 
vitamin – treated group. A detailed inclusion criterion for participant recruitment for the 107 
migraine trial is described in the study by Menon.S et al 2012[14]. Briefly participants were 108 
included if they had suffered from migraine for more than 5 years and had a current diagnosis 109 
of MA (>90% of their migraine were associated with aura), and a 1 year history of severe, 110 
long-lasting attacks MA episodes with severe headaches lasting 4 to 72 hours and had a 111 
family history of migraine. Participants were excluded if they were pregnant or suffered from 112 
a clinically recognised cardiovascular or neuropsychiatric condition (e.g depression and 113 
anxiety) as reported by the participant at the time of the screening process to identify their 114 
eligibility for the trial. All participants were instructed to cease all vitamin supplementation 2 115 
weeks prior to commencement of the trial [14].  Three participants dropped out before the 116 
commencement of the trial and the remaining 242 participants received baseline assessment 117 
and commenced the trial. In the vitamin treated group there were 119 participants and in the 118 
placebo group there were 123 participants. Forty four participants were lost to follow up 119 
because of lack of compliance and 162 participants completed the trial (76 vitamin and 86 120 
placebo), Diet diaries were successfully completed for 141 participants. The remaining 121 
participants either did not complete the diet diary or the diary was not successfully retrieved 122 
from the participants after the trial ended..  123 
  124 
Baseline Assessment and genotyping 125 
Total fasting plasma homocysteine, and serum folate concentrations were taken at baseline 126 
and at the conclusion of the six month trial intervention. The plasma homocysteine (µmol/l), 127 
serum folate (nmol/l), Serum B6 (nmol/L) and serum B12 (pmol/L) were measured in an 128 
accredited laboratory. Genotype assessment was performed by extracting DNA from the 129 
participants’ blood and analysed using standard techniques described in Lea et al 2004[5]. 130 
Participants were assessed for migraine disability using the Migraine Disability Assessment 131 
Score (MIDAS) Instrument, which provides a measure of productive days lost to migraine 132 
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headache in the previous 3 months. Questions 6 and 7 of the MIDAS instrument were on 133 
migraine frequency and head pain severity respectively. Participants were asked to complete 134 
a MIDAS prior to starting the trial, 3 months after starting the trial and the end of the 6 month 135 
intervention of the trial. 136 
  137 
Dietary Assessment Tool 138 
The dietary assessment tool used in this trial was designed to focus on foods that were rich 139 
sources of folate, >200ug/100g according to the Nutrient Tables for use in Australia 140 
(NUTTAB) 2006 Composition Table and was created to document the subject’s daily food 141 
consumption, with an emphasis on folate consumption. A day consisted of a breakfast, lunch, 142 
dinner and snack section. Participants were instructed to indicate what they ate at each 143 
corresponding meal time and to write down “other food” items that they had consumed that 144 
was not on the list of the foods given in the diet diary provided. Subjects were advised that 145 
one serve of food was equal to 100g and were instructed to indicate if fruits and vegetable 146 
consumed were cooked (Fried, boiled, baked) or raw.  Participants were advised to complete 147 
one diary before commencing the trial and one diary for every fortnight of the trial duration. 148 
  149 
Diet Diary Analysis 150 
Analysis of estimated dietary folate intake was performed using the nutrient analysis software 151 
FoodWorks Professional (Version 6, 2009, Xyris Software, Brisbane, Australia). The TFF, 152 
FA and DFE content of each diet diary completed by each participant was analysed. In 153 
instances where participants did not specify cooking techniques an unspecified option (Not 154 
Specified-NFS) was always selected. If serve sizes were not specified, a ‘Standard’ serve size 155 
was selected as specified by FoodWorks. In instances where FoodWorks did not have a 156 
specific food item in its data base, the closest possible option was selected. All assumptions 157 
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were made to be as consistent as possible. Diet diary data was excluded if folate intake was 158 
not reported within two weeks of relevant biomarker measurements. 159 
  160 
Assessment of Folate Intake 161 
Total folate intakes were computed using data from diet diary. The bioavailability of food 162 
folate is lower than that of folic acid added to fortified foods and dietary supplements. The 163 
DFE conversion of TFF was therefore used to account for differential bioavailability. In 164 
Australia, the National Health and Medical Research Council (NHMRC, 2006) calculate DFE 165 
as:  166 
DFE= (Food Folate µg) + (Folic acid µg x 1.67). 167 
DFE, TFF and FA were used in the analysis of folate intake in this study.  168 
  169 
Statistical Analysis  170 
All analyses were performed using the Statistical Package for Social Sciences (SPSS version 171 
21.0). Average dietary folate (TFF, FA and DFE) serum folate and plasma homocysteine 172 
concentration means were determined by descriptive analysis. The relationship between 173 
migraine clinical variables (migraine frequency, MIDAS and migraine pain severity), 174 
biochemical variables (Serum folate, serum B6, B12 and plasma folate) and dietary folate 175 
consumption (DFE, FF and TFF) was analysed using Pearson’s correlation test. Linear 176 
regression analysis was performed using the the “Enter” method, to determine the predictors 177 
of migraine frequency, severity and disability. All tests were two- tailed. Significance was 178 
defined as P < 0.05 level. 179 
  180 
Results 181 
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Diet diaries were successfully collected from 141 participants who were then genotyped for 182 
the MTHFRC677T polymorphism .In the current study, 181 participants had the C allele and 183 
101 participants had the T allele for the MTHFR C677T variant (MTHFR C677T genotype 184 
frequency- CC: 63, CT:55, TT: 23). Biomarker correlations were only performed on diet 185 
diaries that were completed within two weeks of blood tests. The dietary folate intake of the 186 
participants calculated using foodworks was 551.78 ± 19.7 DFE and well above the Required 187 
Daily Intake (RDI) of 400µg DFE. The ratio (%) of individuals who consumed more than 188 
RDI of DFE 400µg were 70.2% (n=99). The DFE intake ranges from 161µg to 1286 µg. The 189 
mean homocysteine level for the population tested in this study was 11.65µmol/l. A positive 190 
Pearson’s correlation was found between DFE consumption and serum folate (r = 0.209, P= 191 
0.019). An inverse positive correlation was also observed between DFE consumption and 192 
migraine frequency (r =-0.200, P= 0.024). MIDAS was positively correlated to migraine pain 193 
severity (r = 0.175, P =0.039). An inverse significant relation was also observed between 194 
serum folate levels and plasma homocysteine levels (r= -0.276, P= 0.002).  195 
Regression analysis was used to test if folate consumption and the MTHFR genotype 196 
significantly predicted serum folate levels. The results of the regression indicated that DFE 197 
consumption predicted 4.4% of the variance [R2 =0.044, P= 0.019, 95% CI (-0.002, -0.20)], 198 
FA consumption predicted 3.7% of the variance [R2 =0.037, P= 0.059, 95% CI (-0.01, -199 
0.020) and TFF consumption predicted 2.6% of the variance in serum folate levels (R2 200 
=0.026, P= 0.073, 95% CI (-0.001, 0.023)]. Folate consumption models were also run 201 
including MTHFR genotype as a possible confounding factor in a multivariate analysis; 202 
however the MTHFR genotype was not a significant contributor for serum folate levels. 203 
 Univariate analysis was performed on variables: B6, B12, serum folate and the MTHFR 204 
C677T genotype to determine significant predictors of plasma homocysteine levels. Serum 205 
B12 [R2 =0.053, CI (-0.011,-0.002) P= 0.007] and serum folate [R2 =0.165, CI (-0.222, -0.048) 206 
P= 0.003] levels were significant factors in determining plasma homocysteine levels. 207 
However when multivariate analysis was performed including all variables in regression 208 
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using the “Enter” method, only serum folate was found to be a significant factor of plasma 209 
homocysteine levels [R2 =0.173, B= -0.122, P= 0.063, 95% CI (-0.219, -0.024)]. Folate 210 
consumption (DFE, FA and TFF) were not significantly related to plasma homocysteine 211 
levels (P>0.05).When folate consumption and migraine outcomes were tested in univariate 212 
regression analysis, it was observed that DFE consumption [R2= 0.040, P= 0.024, CI (-0.002, 213 
-0.002)] and in particular FA consumption [R2= 0.080, P=0.004, CI (-0.006, -0.001)] was 214 
significantly related to migraine frequency (Table 1).In multiple regression analysis, DFE 215 
[R2= 0.201, P= 0.001, 95% CI (-0.004, -0.001)] and FA [R2= 0.255, P= 0.002, 95% CI (-216 
0.005, -0.001)] consumption adjusted for B6, B12, plasma homocysteine levels and the 217 
MTHFR genotype, were significantly related to migraine frequency (Figure 1 and 2). Serum 218 
folate levels adjusted for serum B6 and B12, plasma homocysteine levels and the MTHFR 219 
genotype were not significantly related to migraine frequency [R2= 0.025, P=0.956, CI (-220 
0.04, 0.031)].  221 
When data was stratified by the MTHFR genotype, it was observed that T allele carriers had 222 
consumed the most amounts of DFE (561.3ug) and TFF(486.83ug) but the least amount of 223 
FA(139.8ug) compared to the CC genotype carriers (DFE: 541.3ug, TFF: 455.13ug, FA: 224 
161.62ug). It was also observed that the T allele carriers had higher plasma homocysteine 225 
levels (12.0µmol/L) and lower serum B12 (309.03pmol/L) and serum folate levels 226 
(29.1nmol/L) compared to the CC genotype carriers (Homocysteine: 11.4µmol/L, B12: 227 
314.36pmol/L, Serum Folate: 30.3.nmol/L). The percentage of T allele carriers experiencing 228 
an average of 3 to 6 migraines in 3 months was 32.4% compared to 24.5% in the CC 229 
genotype carriers. Linear regression did not observe a significant relationship between 230 
MTHFR C677T genotype and biochemical variables (P >0.05) or migraine outcomes (P 231 
>0.05). Further regression analysis observed that in individuals with the CC genotype, 232 
migraine frequency was significantly inversely related to FA consumption [R2= 0.077, P= 233 
0.029, CI (-0.009, 0.005)] (Table 2).  234 
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Univariate analysis and multivariate analysis adjusted for B6, B12, plasma homocysteine levels 235 
and the MTHFR C677T genotype did not identify a significant relationship between folate 236 
consumption (DFE, FA , TFF) or serum folate levels and migraine associated disabilities 237 
such MIDAS and migraine pain severity scores (P > 0.05). 238 
  239 
Discussion 240 
A possible interplay between genetic and environmental factors has been the basis of 241 
migraine pathophysiology hypothesised to date [15]. Recent studies have reported a higher 242 
incidence of the co-occurrence of ischemic cardiocerebrovascular disease (CVD) and 243 
migraine [16-20]. This incidence seems to be increased in MA sufferers [21]. Elevated 244 
plasma Hcy levels have been reported to increase the risk of atherosclerotic vasculopathy and 245 
act as an independent risk factor for CVD [22]. An increase in total Hcy concentration has 246 
also been recently reported in migraineurs specifically in those with MA [23]. It is plausible 247 
that homocysteine levels may be involved in both MA and CVD pathophysiology. Reasons 248 
for hyperhomocysteinemia may include mutations in homocysteine metabolising genes such 249 
as MTHFR, MTRR and Cystathionin Beta Synthase (CBS) or possible nutritional 250 
deficiencies in cofactors involved in homocysteine metabolism [12]. 251 
  252 
The current study investigated the association between dietary folate consumption, MTHFR 253 
genotype and migraine associated disability in a cohort of female MA sufferers. This may be 254 
the only study of its kind to analyse food folate consumption by examining folate 255 
consumption in three different components: Total Food Folate (TFF), the fortified folic acid 256 
(FA) content of foods and the Dietary folate equivalent (DFE) in food consumed in 257 
migraineurs. The results of this study observed a significant link between increasing serum 258 
folate levels and increasing DFE consumption and this significance most probably 259 
contributed to the total consumption of FA more than TFF. However the results also show 260 
that DFE consumption and FA consumption only account for 4.4% and 3.7% respectively, of 261 
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serum folate levels. Serum folate levels were significantly correlated to decreasing plasma 262 
homocysteine levels as expected in the current study, however there was no significant link 263 
observed between serum folate levels and migraine frequency, MIDAS or pain severity. 264 
Folate mainly taken up by developing erythrocytes reflects time integrated intake and is 265 
therefore considered to be a measure of long term folate status, while serum folate 266 
predominantly reflects transitory changes in folate concentration [24]. Red blood cell folate 267 
may have provided a more accurate measurement of folate levels in the participants of this 268 
trial compared to serum folate measurement. Other influencing factors of serum folate levels 269 
are the differing acute post-absorptive plasma kinetics of folate and the challenges in 270 
accurately determining dietary folate bioavailability [25].  271 
In the migraine population tested in the current study, a significant correlation between folate 272 
consumption and plasma homocysteine levels was not observed. This finding is contrary to 273 
many previous studies that have observed a significant inverse relationship between folate 274 
consumption and homocysteine levels in plasma [26-28]. The “FoodWorks” software utilised 275 
in this trial did not have several food items that were popular amongst the participants of this 276 
trial. The closest food match was selected, for example, “Raw spinach” was selected in place 277 
of rocket. This may have affected folate consumption measurement as food substitutes used 278 
may not have been the most accurate comparisons. Secondly the lack of confounding factors 279 
analysed in the current trial may have also influenced the lack of association observed 280 
between plasma homocysteine levels and dietary folate intake. The study did not collect 281 
demographic information such as participant smoking habits, blood pressure or blood 282 
cholesterol levels. Dyslipidemia, hypertension and smoking have been shown to effect serum 283 
folate and plasma homocysteine levels [29]. 284 
A major finding of this study is the significant inverse relation observed between DFE and 285 
more specifically FA consumption and migraine frequency. It was also observed that in 286 
individuals with the CC genotype for the MTHFR C677T variant, increasing levels of FA 287 
consumption significantly related to decreasing migraine frequency. T allele carriers who had 288 
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on average consumed less FA than CC genotype carriers showed no correlation between FA 289 
consumption and migraine frequency. Although the current study did not find a significant 290 
correlation between the MTHFR C677T genotype and migraine frequency or homocysteine 291 
levels, it was observed that the T allele carriers, albeit by a small margin, had higher migraine 292 
frequency and plasma homocysteine levels compared to individuals with the CC genotype for 293 
the MTHFR C677T variant. Naturally occurring folate found in food is present in the 294 
reduced, polyglutamated form with methyl or formyl as the one carbon substitution [30, 31]. 295 
Folic acid found in fortified food and supplements, is a synthetic, fully oxidised 296 
monoglutamate form of folate and is reduced to tetrahydrofolate prior to its participation in a 297 
metabolic reaction [32]. Relative to naturally found folate, folic acid has a higher 298 
bioavailability, which is defined as the proportion of ingested folate that is absorbed and can 299 
be used for metabolic processes [33]. Although there is a broad consensus that folic acid is 300 
more bioavailable than naturally found food folate, there are some intervention trials with 301 
food that have reported similar improvements in folate status compared with equimolar or 302 
small doses of folic acid from fortified foods or supplements[34-36]. 303 
  304 
Previous clinical trials by Lea et al 1999 and Menon at al 2011 have provided evidence that 305 
homocysteine lowering by folic acid supplementation can reduce migraine disability and that 306 
this effect may be modified by polymorphisms in genes coding for key enzymes that affect 307 
folate metabolism, such as the MTHFR genotype [13, 14]. T allele carriers of the MTHFR 308 
C677T genotype with a 35% to 70% reduction in their enzymatic rate are genetically slower 309 
in homocysteine metabolism [37]. The findings of the current study, as well as those from 310 
previous migraine trials, suggest that individuals who carry the T allele for the MTHFR 311 
C677T variant, may require an increase in folate consumption, specifically the more 312 
bioavailable FA[38, 39], to experience reduced migraine frequency and possibly other 313 
associated symptoms as well [13, 14]. 314 
 315 
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Certain limitations of this study include the small participant sample size which may not offer 316 
a good representation of the female Caucasian population suffering from MA and their 317 
dietary folate levels. It should also be noted that the dietary information from the migraineurs 318 
of the current study was also obtained prior to the implementation of the mandatory folate 319 
fortification in Australia. Mandatory folate fortification was implemented in Australia in 320 
September 2009. Brown et al reported a significant increase in serum folate levels between 321 
prefortification folate serum concentrations and serum folate concentrations taken 322 
approximately 6 months post fortification [40]. A recent study by Dugbaza et al 2012 that 323 
investigated the levels of total dietary folic acid intake following the mandatory folic acid 324 
fortification reported an increase of 2.5 times in folic acid consumption in the Australian 325 
adult population[41]. Among females with low intake of folate (represented by the tenth 326 
percentile of intake), mandatory fortification has increased their estimated intake from less 327 
than 5% to 75% of the recommended amount [41]  328 
The premise of mandatory folate fortification policy was to reduce the incidence of Neural 329 
Tube Defects: however secondary health benefits may result, such as the potential role of 330 
decreasing homocysteine concentrations in reducing cardiovascular disease as well as 331 
migraine frequency and disability. A long term follow up population study is necessary to 332 
investigate if mandatory folate fortification results in a decrease in migraine incidence in 333 
Australia and if it successfully translates to a decrease in migraine associated disability (work 334 
place absenteeism due to migraine) and positively impacts on the financial burden of 335 
migraine in the country’s economy.  336 
 337 
Conclusion 338 
An increase in dietary folate, especially the more bioavailable FA consumption levels may 339 
effectively reduce migraine frequency in female migraineurs in the investigated study. If this 340 
is a causative relationship, then the T allele carriers of the MTHFR C677T variant may need 341 
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higher levels of FA compared to CC genotype carriers to experience a significant reduction in 342 
their migraine frequency. 343 
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 514 
 515 
 516 
 517 
 518 
 519 
 520 
Tables 521 
 522 
 Table 1:  Folate consumption predictors of migraine frequency in univariate regression 523 
analysis.  524 
 525 
Model R2 B P 95% CI 
Lower Higher
DFE 0.040 -0.001 0.024* -0.002 0.002 
FA 0.080 -0.004 0.004* -0.006 -0.001 
TFF 0.024 -22.915 0.080 -48.818 2.989 
 526 
Univariate regression analysis of folate consumption and migraine frequency showed 527 
significant links between Dietary folate equivalent (DFE) and Folic acid (FA) consumption 528 
and migraine frequency. 95% CI = 95% confidence interval. *Significance was taken at P≤ 529 
0.05.Table 2: Linear regression analysis exploring the influence of folate consumption 530 
on migraine frequency, when stratified by the MTHFR C677T genotype.  531 
Model R2 P B 95% CI 
Lower Higher
CC DFE 0.058 0.069 -0.001 -0.002 0.0009
 FA 0.106 0.029* -0.004 -0.007 0.0004
 TFF 0.016 0.156 -0.001 -0.003 0.0005
22 
 
 532 
 533 
 534 
 535 
 536 
 537 
 538 
Linear regression analysis of folate consumption and migraine frequency, stratified by the 539 
Methylenetetrahydrofolate reductase gene variant C677T (MTHFR C677T) showed that in 540 
individuals with the CC genotype, migraine frequency is inversely related to FA 541 
consumption. 95% CI = 95% confidence interval. *Significance was taken at P≤ 0.05. 542 
Figures 543 
Figure 1:  A scatterplot showing the relationship between DFE consumption and migraine 544 
frequency. 545 
CT/TT DFE 0.028 0.176 -0.001 -0.002 0.0004
 FA 0.061 0.071 -0.004 -0.008 0.0003
 TFF 0.016 0.301 -0.001 -0.003 0.001 
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 546 
 547 
 548 
A regression analysis with the “Enter” method between independent (B6, B12, plasma 549 
homocysteine levels, DFE consumption and MTHFR C677T genotype) was performed on 550 
migraine frequency data. The analysis revealed that DFE consumption significantly affects 551 
migraine frequency. 552 
 553 
 554 
 555 
Figure 2: A scatterplot showing the relationship between FA consumption and migraine 556 
frequency. 557 
DFE consumption (µg)
M
ig
ra
in
e f
re
qu
en
cy
 
y= 2.31 + ‐8.78E – 4*X 
24 
 
 558 
 559 
A regression analysis with the “Enter” method between independent variables (B6, B12, 560 
plasma homocysteine levels, FA consumption and MTHFR C677T genotype) was performed 561 
on migraine frequency data. The analysis revealed that FA consumption significantly affects 562 
migraine frequency. 563 
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